Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc.HRMY · Entity 4381 | CHIEF COMMERCIAL OFFICER | March 03, 2025 | March 05, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Harmony Biosciences Holdings, Inc.
Report date March 03, 2025 · Filed March 05, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2025-03-03 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2025-03-03 · Exercise / conversion · Acquired 4,869 · Balance 4,869 Row 2 · 2025-03-03 · Sale · Disposed 4,369 · Balance 500 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.08 to $32.97. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2025-03-03 · Sale · Disposed 500 · Balance 0 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.14 to $33.39. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $8.22 · Expires 2030-03-04 | Direct | 0 |
Reported balance
After 2025-03-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-03-03 · Exercise / conversion · Disposed 4,869 · Balance 0 F4: The stock option vests in five equal annual installments beginning on March 1, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.08 to $32.97. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.14 to $33.39. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The stock option vests in five equal annual installments beginning on March 1, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 08, 2024 Filed Mar 11, 2024 21:17 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 194 | $8.22 | $1,594.68 |
DisclosureSEC source: 0001415889-24-007527 · form4-03112024_090322.xml · nonDerivative · entry 1 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 194 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 24, 2024 Filed Jan 26, 2024 21:55 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantRestricted Stock Units · Derivative | 10,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-001871 · form4-01262024_090124.xml · derivative · entry 2 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,750 Underlying: Common Stock · 10,750 shares Expires not disclosed F2 · derivative.exercise_price: The restricted stock units were granted on January 24, 2024. The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F2 · derivative.exercise_date: The restricted stock units were granted on January 24, 2024. The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F2 · derivative.expiration_date: The restricted stock units were granted on January 24, 2024. The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. Read SEC document |
| January 24, 2024 Filed Jan 26, 2024 21:55 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantStock Option · Derivative | 52,500 | $0.00 Strike: $30.69 | $0.00 |
DisclosureSEC source: 0001415889-24-001871 · form4-01262024_090124.xml · derivative · entry 1 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,500 Underlying: Common Stock · 52,500 shares Expires 2034-01-24 F1 · derivative.exercise_date: The stock option vests with respect to 25% of the underlying shares on January 24, 2025, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| October 04, 2023 Filed Nov 8, 2023 21:02 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantRestricted Stock Units · Derivative | 150,000 | $0.00 Strike: $31.78 | $0.00 |
DisclosureSEC source: 0001415889-23-014890 · form4-11082023_091102.xml · derivative · entry 1 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires not disclosed F1 · derivative.exercise_date: The restricted stock units were granted on October 4, 2023. 40% of the restricted stock units shall vest on September 30, 2024 and 30% shall vest on each of September 30, 2025 and September 30, 2026. Each restricted unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F1 · derivative.expiration_date: The restricted stock units were granted on October 4, 2023. 40% of the restricted stock units shall vest on September 30, 2024 and 30% shall vest on each of September 30, 2025 and September 30, 2026. Each restricted unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 20:07 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 2,434 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0001415889-22-010215 · form4-10042022_011050.xml · derivative · entry 5 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,435 Underlying: Common Stock · 2,434 shares Expires 2028-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vests in five equal annual installments beginning on October 1, 2019. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 20:07 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 9,739 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0001415889-22-010215 · form4-10042022_011050.xml · derivative · entry 4 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,739 shares Expires 2027-10-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vests in five equal annual installments beginning on October 1, 2018. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 20:07 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 2,791 | $45.47 | $126,912.35 |
DisclosureSEC source: 0001415889-22-010215 · form4-10042022_011050.xml · nonDerivative · entry 3 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.97 to $45.75. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 20:07 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 9,382 | $44.45 | $417,003.63 |
DisclosureSEC source: 0001415889-22-010215 · form4-10042022_011050.xml · nonDerivative · entry 2 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,791 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.93 to $44.91. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 20:07 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 12,173 | $8.22 | $100,062.06 |
DisclosureSEC source: 0001415889-22-010215 · form4-10042022_011050.xml · nonDerivative · entry 1 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,173 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 22, 2022 Filed Aug 23, 2022 20:11 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 28,971 | $0.00 Strike: $24.00 | $0.00 |
DisclosureSEC source: 0001415889-22-008969 · form4-08232022_010849.xml · derivative · entry 4 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,914 Underlying: Common Stock · 28,971 shares Expires 2030-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vests in five equal annual installments beginning on August 21, 2021. F5 · balance_after: The Form 4 filed by the reporting person on March 2, 2022, overstated the number of securities owned following the reported transaction by 200 shares. The amount of securities reported herein reflects the correct number of securities owned following the transactions reported on this Form 4. Read SEC document |
| August 22, 2022 Filed Aug 23, 2022 20:11 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 2,321 | $47.56 | $110,395.35 |
DisclosureSEC source: 0001415889-22-008969 · form4-08232022_010849.xml · nonDerivative · entry 3 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.41 to $47.70. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 22, 2022 Filed Aug 23, 2022 20:11 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 26,650 | $46.95 | $1,251,332.10 |
DisclosureSEC source: 0001415889-22-008969 · form4-08232022_010849.xml · nonDerivative · entry 2 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,321 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.40 to $47.39. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 22, 2022 Filed Aug 23, 2022 20:11 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 28,971 | $24.00 | $695,304.00 |
DisclosureSEC source: 0001415889-22-008969 · form4-08232022_010849.xml · nonDerivative · entry 1 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,971 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 21:07 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 14,471 | $0.00 Strike: $24.00 | $0.00 |
DisclosureSEC source: 0001104659-22-042846 · tm2211710-1_4seq1.xml · derivative · entry 4 Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,085 Underlying: Common Stock · 14,471 shares Expires 2030-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vests in five equal annual installments beginning on August 21, 2021. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 21:07 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 7,706 | $49.87 | $384,277.41 |
DisclosureSEC source: 0001104659-22-042846 · tm2211710-1_4seq1.xml · nonDerivative · entry 3 Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.69 to $50.02. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 21:07 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 6,765 | $49.36 | $333,892.66 |
DisclosureSEC source: 0001104659-22-042846 · tm2211710-1_4seq1.xml · nonDerivative · entry 2 Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,706 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.69 to $49.68. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 21:07 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 14,471 | $24.00 | $347,304.00 |
DisclosureSEC source: 0001104659-22-042846 · tm2211710-1_4seq1.xml · nonDerivative · entry 1 Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,471 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 21:05 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 4,869 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0001104659-22-029266 · tm228148-1_4seq1.xml · derivative · entry 6 Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,607 Underlying: Common Stock · 4,869 shares Expires 2030-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vests in five equal annual installments beginning on March 4, 2021 Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 21:05 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 4,869 | $40.04 | $194,957.68 |
DisclosureSEC source: 0001104659-22-029266 · tm228148-1_4seq1.xml · nonDerivative · entry 4 Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.74 to $40.39. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 21:05 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 4,869 | $8.22 | $40,023.18 |
DisclosureSEC source: 0001104659-22-029266 · tm228148-1_4seq1.xml · nonDerivative · entry 3 Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,869 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:05 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 10,041 | $0.00 Strike: $24.00 | $0.00 |
DisclosureSEC source: 0001104659-22-029266 · tm228148-1_4seq1.xml · derivative · entry 5 Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,556 Underlying: Common Stock · 10,041 shares Expires 2030-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vests in five equal annual installments beginning on August 21, 2021. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:05 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 10,041 | $40.00 | $401,653.05 |
DisclosureSEC source: 0001104659-22-029266 · tm228148-1_4seq1.xml · nonDerivative · entry 2 Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.06. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:05 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 10,041 | $24.00 | $240,984.00 |
DisclosureSEC source: 0001104659-22-029266 · tm228148-1_4seq1.xml · nonDerivative · entry 1 Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,041 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2022 Filed Feb 18, 2022 21:05 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 200 | $0.00 Strike: $24.00 | $0.00 |
DisclosureSEC source: 0001104659-22-025148 · tm227120-1_4seq1.xml · derivative · entry 6 Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,397 Underlying: Common Stock · 200 shares Expires 2030-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vests in five equal annual installments beginning on August 21, 2021. Read SEC document |
| February 17, 2022 Filed Feb 18, 2022 21:05 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 4,259 | $40.02 | $170,423.89 |
DisclosureSEC source: 0001104659-22-025148 · tm227120-1_4seq1.xml · nonDerivative · entry 4 Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.01 to $40.02. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 17, 2022 Filed Feb 18, 2022 21:05 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 200 | $24.00 | $4,800.00 |
DisclosureSEC source: 0001104659-22-025148 · tm227120-1_4seq1.xml · nonDerivative · entry 3 Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 21:05 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 4,259 | $0.00 Strike: $24.00 | $0.00 |
DisclosureSEC source: 0001104659-22-025148 · tm227120-1_4seq1.xml · derivative · entry 5 Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,597 Underlying: Common Stock · 4,259 shares Expires 2030-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vests in five equal annual installments beginning on August 21, 2021. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 21:05 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 4,259 | $40.05 | $170,590.84 |
DisclosureSEC source: 0001104659-22-025148 · tm227120-1_4seq1.xml · nonDerivative · entry 2 Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.21. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 21:05 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 4,259 | $24.00 | $102,216.00 |
DisclosureSEC source: 0001104659-22-025148 · tm227120-1_4seq1.xml · nonDerivative · entry 1 Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,259 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 06, 2022 Filed Jan 10, 2022 21:07 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 2,435 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0001104659-22-002722 · tm221863-2_4seq1.xml · derivative · entry 6 Dierks Jeffrey · CIK 0001821102 · Director · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,869 Underlying: Common Stock · 2,435 shares Expires 2028-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option is currently vested with respect to 0 shares, and will vest with respect to the remainder of the shares in two equal annual installments beginning on October 1, 2022. Read SEC document |
| January 06, 2022 Filed Jan 10, 2022 21:07 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 3,690 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0001104659-22-002722 · tm221863-2_4seq1.xml · derivative · entry 5 Dierks Jeffrey · CIK 0001821102 · Director · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,739 Underlying: Common Stock · 3,690 shares Expires 2027-10-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option is currently vested with respect to 0 shares, and will vest with respect to the remainder of the shares on October 1, 2022. Read SEC document |
| January 06, 2022 Filed Jan 10, 2022 21:07 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 424 | $41.23 | $17,481.90 |
DisclosureSEC source: 0001104659-22-002722 · tm221863-2_4seq1.xml · nonDerivative · entry 4 Dierks Jeffrey · CIK 0001821102 · Director · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.08 to $41.39. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 06, 2022 Filed Jan 10, 2022 21:07 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 4,302 | $40.53 | $174,379.42 |
DisclosureSEC source: 0001104659-22-002722 · tm221863-2_4seq1.xml · nonDerivative · entry 3 Dierks Jeffrey · CIK 0001821102 · Director · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 424 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.07 to $41.02. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 06, 2022 Filed Jan 10, 2022 21:07 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 1,399 | $39.60 | $55,396.48 |
DisclosureSEC source: 0001104659-22-002722 · tm221863-2_4seq1.xml · nonDerivative · entry 2 Dierks Jeffrey · CIK 0001821102 · Director · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,726 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.05 to $40.04. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 06, 2022 Filed Jan 10, 2022 21:07 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 6,125 | $8.22 | $50,347.50 |
DisclosureSEC source: 0001104659-22-002722 · tm221863-2_4seq1.xml · nonDerivative · entry 1 Dierks Jeffrey · CIK 0001821102 · Director · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,125 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 20:45 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 3,952 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0000899243-21-042746 · doc4.xml · derivative · entry 5 Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,476 Underlying: Common Stock · 3,952 shares Expires 2030-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option is currently vested with respect to 0 shares, and will vest with respect to the remainder of the shares in four equal annual installments beginning on March 1, 2022. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 20:45 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 6,048 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0000899243-21-042746 · doc4.xml · derivative · entry 4 Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,429 Underlying: Common Stock · 6,048 shares Expires 2027-10-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option is currently vested with respect to 3,690 shares, and will vest with respect to the remainder of the shares on October 1, 2022. F5 · balance_after: Reflects 785 additional stock options which were erroneously reported as exercised on the Form 4 filed by the reporting person on September 3, 2021, but which were actually exercised from the tranche which expires on October 1, 2028. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 20:45 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 2,946 | $42.44 | $125,014.98 |
DisclosureSEC source: 0000899243-21-042746 · doc4.xml · nonDerivative · entry 3 Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.03 to $43.00. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 20:45 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 7,054 | $41.36 | $291,724.52 |
DisclosureSEC source: 0000899243-21-042746 · doc4.xml · nonDerivative · entry 2 Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,946 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.03 to $42.02. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 20:45 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 10,000 | $8.22 | $82,200.00 |
DisclosureSEC source: 0000899243-21-042746 · doc4.xml · nonDerivative · entry 1 Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 07, 2021 Filed Sep 10, 2021 01:34 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 917 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0000899243-21-035508 · doc4.xml · derivative · entry 4 Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,428 Underlying: Common Stock · 917 shares Expires 2030-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option is currently vested with respect to 4,869 shares, and will vest with respect to the remainder of the shares in four equal annual installments beginning on March 1, 2022. Read SEC document |
| September 07, 2021 Filed Sep 10, 2021 01:34 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 4,083 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0000899243-21-035508 · doc4.xml · derivative · entry 3 Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,304 Underlying: Common Stock · 4,083 shares Expires 2028-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is currently vested with respect to 4,868 shares, and will vest with respect to the remainder of the shares in three equal annual installments beginning on October 1, 2021. F4 · balance_after: Reflects the exercise of 785 stock options on September 1, 2021, which was reported on the Form 4 filed by the reporting person on September 3, 2021, but erroneously reflected as an exercise of the tranche which expires on October 2, 2027, rather than the tranche which expires on October 1, 2028. Read SEC document |
| September 07, 2021 Filed Sep 10, 2021 01:34 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 5,000 | $37.00 | $185,000.00 |
DisclosureSEC source: 0000899243-21-035508 · doc4.xml · nonDerivative · entry 2 Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 07, 2021 Filed Sep 10, 2021 01:34 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 5,000 | $8.22 | $41,100.00 |
DisclosureSEC source: 0000899243-21-035508 · doc4.xml · nonDerivative · entry 1 Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 20:32 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 10,000 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0000899243-21-035132 · doc4.xml · derivative · entry 4 Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,692 Underlying: Common Stock · 10,000 shares Expires 2027-10-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option is currently vested with respect to 20,707 shares, and will vest with respect to the remainder of the shares in two equal annual installments beginning on October 2, 2021. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 20:32 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 3,302 | $34.26 | $113,115.29 |
DisclosureSEC source: 0000899243-21-035132 · doc4.xml · nonDerivative · entry 3 Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $ 33.95 to $34.69. The reporting person undertakes to provide the issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 20:32 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 6,698 | $33.30 | $223,009.91 |
DisclosureSEC source: 0000899243-21-035132 · doc4.xml · nonDerivative · entry 2 Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,302 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.90 to $33.63. The reporting person undertakes to provide the issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 20:32 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 10,000 | $8.22 | $82,200.00 |
DisclosureSEC source: 0000899243-21-035132 · doc4.xml · nonDerivative · entry 1 Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 27, 2021 Filed Aug 30, 2021 20:30 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 3,400 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0000899243-21-034515 · doc4.xml · derivative · entry 6 Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,692 Underlying: Common Stock · 3,400 shares Expires 2027-10-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option is currently vested with respect to 20,707 shares, and will vest with respect to the remainder of the shares in two equal annual installments beginning on October 2, 2021. Read SEC document |
| August 27, 2021 Filed Aug 30, 2021 20:30 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 3,400 | $35.18 | $119,603.84 |
DisclosureSEC source: 0000899243-21-034515 · doc4.xml · nonDerivative · entry 4 Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.045. The reporting person undertakes to provide the issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.